PARTNER 3 Trial demonstrated Edwards TAVR is superior compared to surgery

* Compared to 2.9% death or disabling stroke at 1 year for surgery (P=0.03). PARTNER 3 Trial proved SAPIEN 3 TAVR is superior to surgery on the primary endpoint (all-cause death, all stroke, and rehospitalization) and multiple prespecified secondary endpoints.1,2